Interferon-α2b induced anemia in severe coronavirus disease 2019 patients: a single centered, retrospective study

References

• Chen T, Dai Z, Mo P, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci. 2020;75(9):1788–1795.
   PubMed Web of Science ®Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481.
   PubMed Web of Science ®Google Scholar
• Liu X, Liu C, Liu G, et al. COVID-19: progress in diagnostics, therapy and vaccination. Theranostics. 2020;10(17):7821–7835.
   PubMed Web of Science ®Google Scholar
• Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473.
   PubMed Web of Science ®Google Scholar
• Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and Ventilator-Free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307–1316.
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People's Republic of China. Proactive Prevention and Control of Novel Coronavirus Pneumonia by the National Health Commission. Available from: http://www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml
   Google Scholar
• Taneri PE, Gómez-Ochoa SA, Llanaj E, et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(8):763–773.
   PubMed Web of Science ®Google Scholar
• Lazarian G, Quinquenel A, Bellal M, et al. Autoimmune haemolytic anaemia associated with COVID-19 infection. Br J Haematol. 2020;190(1):29–31.
   PubMed Web of Science ®Google Scholar
• Jacobs J, Eichbaum Q. COVID-19 associated with severe autoimmune hemolytic anemia. Transfusion. 2021;61(2):635–640.
   PubMed Web of Science ®Google Scholar
• Bellmann-Weiler R, Lanser L, Barket R, et al. Prevalence and predictive value of anemia and dysregulated iron homeostasis in patients with COVID-19 infection. JCM. 2020;9(8):2429.
   Web of Science ®Google Scholar
• Russmann S, Grattagliano I, Portincasa P, et al. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem. 2006;13(27):3351–3357.
   PubMed Web of Science ®Google Scholar
• Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med. 2004;71(Suppl 3):S17–S21.
   PubMedGoogle Scholar
• Bakheet SA, Alrwashied BS, Ansari MA, et al. CXC chemokine receptor 3 antagonist AMG487 shows potent anti-arthritic effects on collagen-induced arthritis by modifying B cell inflammatory profile. Immunol Lett. 2020;225:74–81.
   PubMed Web of Science ®Google Scholar
• Bakheet SA, Alrwashied BS, Ansari MA, et al. CXCR3 antagonist AMG487 inhibits glucocorticoid-induced tumor necrosis factor-receptor-related protein and inflammatory mediators in CD45 expressing cells in collagen-induced arthritis mouse model. Int Immunopharmacol. 2020;84:106494.
   PubMed Web of Science ®Google Scholar
• Sim GC, Wu S, Jin L, et al. Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2. Oncotarget. 2016;7(24):36074–36091.
   PubMedGoogle Scholar
• Zhou Z, Ren L, Zhang L, et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020;27(6):883–890.
   PubMed Web of Science ®Google Scholar
• Smolders EJ, Thammajaruk N, de Kanter CTMM, et al. Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics. Trop Med Int Health. 2018;23(3):295–305.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Cooper C, Hunyady B, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8(4):212–223.
   PubMed Web of Science ®Google Scholar
• Roomer R, Hansen BE, Janssen HL, et al. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol. 2010;53(3):455–459.
   PubMed Web of Science ®Google Scholar
• Bergamaschi G, Borrelli de Andreis F, Aronico N, et al. Anemia in patients with covid-19: pathogenesis and clinical significance. Clin Exp Med. 2021;21(2):239–246.
   PubMed Web of Science ®Google Scholar
• Faghih Dinevari M, Somi MH, Sadeghi Majd E, et al. Anemia predicts poor outcomes of COVID-19 in hospitalized patients: a prospective study in Iran. BMC Infect Dis. 2021;21(1):170.
   PubMed Web of Science ®Google Scholar
• Lippi G, Mattiuzzi C. Hemoglobin value may be decreased in patients with severe coronavirus disease 2019. Hematol Transfus Cell Ther. 2020;42(2):116–117.
   PubMedGoogle Scholar
• Zhang G, Hu C, Luo L, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364.
   PubMed Web of Science ®Google Scholar
• Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Zhong NS. Clinical characteristics of covid-19 in China. Reply. N Engl J Med. 2020;382(19):1861–1862.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Liang WH, Zhao Y, et al. He JX; China medical treatment expert group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547.
   PubMed Web of Science ®Google Scholar
• Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488–1494.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan. China. Allergy. 2020;75(7):1730–1741.
   PubMed Web of Science ®Google Scholar
• Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med. 2020;1(1):105–113.e4.
   PubMed Web of Science ®Google Scholar
• Pshenichnaya NY, Bulgakova VA, Lvov NI, et al. Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR). Ter Arkh. 2019;91(3):56–63.
   PubMed Web of Science ®Google Scholar
• Knowles SR, Phillips EJ, Dresser L, et al. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis. 2003;37(8):1139–1142.
   PubMed Web of Science ®Google Scholar
• Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 2004;59(5):414–420.
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Dieterich DT; APRICOT study group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–450.
   PubMed Web of Science ®Google Scholar
• Hu CC, Weng CH, Lin CL, et al. Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α. Ren Fail. 2012;34(4):429–434.
   PubMed Web of Science ®Google Scholar
• Alanoglu G, Kilbas S, Arslan C, et al. Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis. Mult Scler. 2007;13(5):683–685.
   PubMed Web of Science ®Google Scholar
• Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017;49:96–102.
   PubMed Web of Science ®Google Scholar
• Wang S, Qin E, Zhi Y, et al. Severe autoimmune hemolytic anemia during pegylated interferon plus ribavirin treatment for chronic hepatitis C: a case report. Clin Case Rep. 2017;5(9):1490–1492.
   PubMed Web of Science ®Google Scholar
• Kato K, Kamezaki K, Shimoda K, et al. Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth. Br J Haematol. 2003;123(3):528–535.
   PubMed Web of Science ®Google Scholar
• de Bruin AM, Demirel O, Hooibrink B, et al. Interferon-γ impairs proliferation of hematopoietic stem cells in mice . Blood. 2013;121(18):3578–3585.
   PubMed Web of Science ®Google Scholar
• de Bruin AM, Libregts SF, Valkhof M, et al. IFNγ induces monopoiesis and inhibits neutrophil development during inflammation. Blood. 2012;119(6):1543–1554.
   PubMed Web of Science ®Google Scholar
• Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells. 2001;19(5):378–387.
   PubMed Web of Science ®Google Scholar
• Sasaki A, Yasukawa H, Shouda T, et al. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem. 2000;275(38):29338–29347.
   PubMed Web of Science ®Google Scholar
• Libregts SF, Gutiérrez L, de Bruin AM, et al. Chronic IFN-γ production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU.1 axis. Blood. 2011;118(9):2578–2588.
   PubMed Web of Science ®Google Scholar
• Rekhtman N, Radparvar F, Evans T, et al. Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Genes Dev. 1999;13(11):1398–1411.
   PubMed Web of Science ®Google Scholar
• Kheansaard W, Mas-Oo-di S, Nilganuwong S, et al. Interferon-gamma induced nitric oxide-mediated apoptosis of anemia of chronic disease in rheumatoid arthritis. Rheumatol Int. 2013;33(1):151–156.
   PubMed Web of Science ®Google Scholar
• Su Q, Liu Y, Li J. Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B. Medicine. 2018;97(34):e12089.
   PubMed Web of Science ®Google Scholar
• Yang Y, Luo R, Cheng Y, et al. Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis. BMC Nephrol. 2020;21(1):122.
   PubMed Web of Science ®Google Scholar
• Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013;62(5):849–859.
   PubMed Web of Science ®Google Scholar
• Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe middle east respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090–1095.
   PubMed Web of Science ®Google Scholar
• Morra ME, Van Thanh L, Kamel MG, et al. Clinical outcomes of current medical approaches for middle east respiratory syndrome: a systematic review and meta-analysis. Rev Med Virol. 2018;28(3):e1977.
   PubMed Web of Science ®Google Scholar
• Cinatl J, Morgenstern B, Bauer G, et al. Treatment of SARS with human interferons. Lancet. 2003;362(9380):293–294.
   PubMed Web of Science ®Google Scholar
• Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat middle east respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother. 2015;70(7):2129–2132.
   PubMed Web of Science ®Google Scholar